Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 179

1.

Novel Microbial-Based Immunotherapy Approach for Crohn's Disease.

Sutcliffe S, Kalyan S, Pankovich J, Chen JMH, Gluck R, Thompson D, Bosiljcic M, Bazett M, Fedorak RN, Panaccione R, Axler J, Marshall JK, Mullins DW, Kabakchiev B, McGovern DPB, Jang J, Coldman A, Vandermeirsch G, Bressler B, Gunn H.

Front Med (Lausanne). 2019 Jul 19;6:170. doi: 10.3389/fmed.2019.00170. eCollection 2019.

2.

Disease detection at the 48-month exit round of the HPV FOCAL cervical cancer screening trial in women per-protocol eligible for routine screening.

Coldman AJ, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan DJ, Lee M, Elwood-Martin R, Gentile L, Peacock S, Stuart GCE, Franco EL, Ogilvie GS.

Int J Cancer. 2019 Jun 27. doi: 10.1002/ijc.32524. [Epub ahead of print]

PMID:
31245842
3.

Evaluation of a validated methylation triage signature for human papillomavirus positive women in the HPV FOCAL cervical cancer screening trial.

Cook DA, Krajden M, Brentnall AR, Gondara L, Chan T, Law JH, Smith LW, van Niekerk DJ, Ogilvie GS, Coldman AJ, Warman R, Reuter C, Cuzick J, Lorincz AT.

Int J Cancer. 2019 May 15;144(10):2587-2595. doi: 10.1002/ijc.31976. Epub 2018 Dec 24.

4.

Comparative performance of human papillomavirus messenger RNA versus DNA screening tests at baseline and 48 months in the HPV FOCAL trial.

Cook DA, Smith LW, Law JH, Mei W, Gondara L, van Niekerk DJ, Ceballos KM, Jang D, Chernesky M, Franco EL, Ogilvie GS, Coldman AJ, Krajden M.

J Clin Virol. 2018 Nov;108:32-37. doi: 10.1016/j.jcv.2018.09.004. Epub 2018 Sep 10.

PMID:
30223252
5.

Effect of Screening With Primary Cervical HPV Testing vs Cytology Testing on High-grade Cervical Intraepithelial Neoplasia at 48 Months: The HPV FOCAL Randomized Clinical Trial.

Ogilvie GS, van Niekerk D, Krajden M, Smith LW, Cook D, Gondara L, Ceballos K, Quinlan D, Lee M, Martin RE, Gentile L, Peacock S, Stuart GCE, Franco EL, Coldman AJ.

JAMA. 2018 Jul 3;320(1):43-52. doi: 10.1001/jama.2018.7464. Erratum in: JAMA. 2018 Dec 4;320(21):2273.

6.

The OncoSim model: development and use for better decision-making in Canadian cancer control.

Gauvreau CL, Fitzgerald NR, Memon S, Flanagan WM, Nadeau C, Asakawa K, Garner R, Miller AB, Evans WK, Popadiuk CM, Wolfson M, Coldman AJ.

Curr Oncol. 2017 Dec;24(6):401-406. doi: 10.3747/co.24.3850. Epub 2017 Dec 20.

7.

Post-Loop Electrosurgical Excision Procedure High-Risk Human Papillomavirus Testing as a Test of Cure: The British Columbia Experience.

Ceballos KM, Lee M, Cook DA, Smith LW, Gondara L, Krajden M, van Niekerk DJ, Coldman AJ.

J Low Genit Tract Dis. 2017 Oct;21(4):284-288. doi: 10.1097/LGT.0000000000000349.

PMID:
28953120
8.

Cancer in First Nations people living in British Columbia, Canada: an analysis of incidence and survival from 1993 to 2010.

McGahan CE, Linn K, Guno P, Johnson H, Coldman AJ, Spinelli JJ, Caron NR.

Cancer Causes Control. 2017 Oct;28(10):1105-1116. doi: 10.1007/s10552-017-0950-7. Epub 2017 Sep 8.

PMID:
28887646
9.

Independent Scientists Provide Guidance for the Future of Cervical Cancer Screening.

Smith L, van Niekerk D, Coldman A, Krajden M, Franco EL, Ogilvie G.

J Obstet Gynaecol Can. 2017 May;39(5):326-327. doi: 10.1016/j.jogc.2017.02.006. No abstract available.

PMID:
28454754
10.

Overview of cancer incidence and mortality among people living with HIV/AIDS in British Columbia, Canada: Implications for HAART use and NADM development.

Chiu CG, Smith D, Salters KA, Zhang W, Kanters S, Milan D, Montaner JSG, Coldman A, Hogg RS, Wiseman SM.

BMC Cancer. 2017 Apr 14;17(1):270. doi: 10.1186/s12885-017-3229-1.

11.

Performance of a quantitative fecal immunochemical test in a colorectal cancer screening pilot program: a prospective cohort study.

Telford J, Gentile L, Gondara L, McGahan C, Coldman A.

CMAJ Open. 2016 Nov 4;4(4):E668-E673. doi: 10.9778/cmajo.20160047. eCollection 2016 Oct-Dec.

12.

Aptima HPV Assay versus Hybrid Capture® 2 HPV test for primary cervical cancer screening in the HPV FOCAL trial.

Cook DA, Smith LW, Law J, Mei W, van Niekerk DJ, Ceballos K, Gondara L, Franco EL, Coldman AJ, Ogilvie GS, Jang D, Chernesky M, Krajden M.

J Clin Virol. 2017 Feb;87:23-29. doi: 10.1016/j.jcv.2016.12.004. Epub 2016 Dec 11.

13.

Disease detection and resource use in the safety and control arms of the HPV FOCAL cervical cancer screening trial.

Coldman AJ, Gondara L, Smith LW, van Niekerk D, Ceballos K, Krajden M, Cook D, Quinlan DJ, Lee M, Stuart GC, Peacock S, Martin RE, Gentile L, Franco EL, Ogilvie GS.

Br J Cancer. 2016 Dec 6;115(12):1487-1494. doi: 10.1038/bjc.2016.368. Epub 2016 Nov 17.

14.

Cervical cancer incidence in British Columbia: Predicting effects of changes from Pap to human papillomavirus screening and of changes in screening participation.

Coldman A, van Niekerk D, Smith L, Ogilvie G.

J Med Screen. 2017 Dec;24(4):195-200. doi: 10.1177/0969141316673673. Epub 2016 Nov 3.

PMID:
27810984
15.

HPV for cervical cancer screening (HPV FOCAL): Complete Round 1 results of a randomized trial comparing HPV-based primary screening to liquid-based cytology for cervical cancer.

Ogilvie GS, Krajden M, van Niekerk D, Smith LW, Cook D, Ceballos K, Lee M, Gentile L, Gondara L, Elwood-Martin R, Peacock S, Stuart G, Franco EL, Coldman AJ.

Int J Cancer. 2017 Jan 15;140(2):440-448. doi: 10.1002/ijc.30454. Epub 2016 Oct 20.

16.

Recommendations for Implementing Human Papillomavirus-Based Cervical Cancer Screening: Lessons Learned from the HPV FOCAL Trial.

Smith L, van Niekerk D, Coldman A, Krajden M, Franco EL, Ogilvie G.

J Obstet Gynaecol Can. 2016 Aug;38(8):723-6. doi: 10.1016/j.jogc.2016.04.009. Epub 2016 Jun 7. No abstract available.

PMID:
27638983
17.

Using the Cancer Risk Management Model to evaluate the health and economic impacts of cytology compared with human papillomavirus DNA testing for primary cervical cancer screening in Canada.

Popadiuk C, Gauvreau CL, Bhavsar M, Nadeau C, Asakawa K, Flanagan WM, Wolfson MC, Coldman AJ, Memon S, Fitzgerald N, Lacombe J, Miller AB.

Curr Oncol. 2016 Feb;23(Suppl 1):S56-63. doi: 10.3747/co.23.2991. Epub 2016 Feb 29.

18.

Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis.

Cromwell I, Ferreira Z, Smith L, van der Hoek K, Ogilvie G, Coldman A, Peacock SJ.

Curr Oncol. 2016 Feb;23(Suppl 1):S14-22. doi: 10.3747/co.23.2914. Epub 2016 Feb 29.

19.

Correlates of women's intentions to be screened for human papillomavirus for cervical cancer screening with an extended interval.

Ogilvie GS, Smith LW, van Niekerk D, Khurshed F, Pedersen HN, Taylor D, Thomson K, Greene SB, Babich SM, Franco EL, Coldman AJ.

BMC Public Health. 2016 Mar 2;16:213. doi: 10.1186/s12889-016-2865-8.

20.

WITHDRAWN: Immunotherapy for advanced renal cell cancer.

Coppin C, Porzsolt F, Autenrieth M, Kumpf J, Coldman A, Wilt TJ.

Cochrane Database Syst Rev. 2015 Dec 29;(12):CD001425. doi: 10.1002/14651858.CD001425.pub3. Review. No abstract available.

PMID:
26713838
21.

Comparison of the Roche cobas® 4800 and Digene Hybrid Capture® 2 HPV tests for primary cervical cancer screening in the HPV FOCAL trial.

Cook DA, Mei W, Smith LW, van Niekerk DJ, Ceballos K, Franco EL, Coldman AJ, Ogilvie GS, Krajden M.

BMC Cancer. 2015 Dec 16;15:968. doi: 10.1186/s12885-015-1959-5.

22.

Cancer incidence among HIV-positive women in British Columbia, Canada: Heightened risk of virus-related malignancies.

Salters KA, Cescon A, Zhang W, Ogilvie G, Murray MC, Coldman A, Hamm J, Chiu CG, Montaner JS, Wiseman SM, Money D, Pick N, Hogg RS.

HIV Med. 2016 Mar;17(3):188-95. doi: 10.1111/hiv.12290. Epub 2015 Aug 12.

23.

Projected Impact of HPV and LBC Primary Testing on Rates of Referral for Colposcopy in a Canadian Cervical Cancer Screening Program.

Coldman AJ, Phillips N, van Niekerk D, Smith L, Krajden M, Cook D, Quinlan DJ, Ehlen T, Miller D, Stuart GC, Peacock S, Martin RE, Franco EL, Ogilvie G.

J Obstet Gynaecol Can. 2015 May;37(5):412-420. doi: 10.1016/S1701-2163(15)30255-3.

PMID:
26168101
24.

Using the Cancer Risk Management Model to evaluate colorectal cancer screening options for Canada.

Coldman AJ, Phillips N, Brisson J, Flanagan W, Wolfson M, Nadeau C, Fitzgerald N, Miller AB.

Curr Oncol. 2015 Apr;22(2):e41-50. doi: 10.3747/co.22.2013.

25.

Reduction in cervical intraepithelial neoplasia in young women in British Columbia after introduction of the HPV vaccine: An ecological analysis.

Ogilvie GS, Naus M, Money DM, Dobson SR, Miller D, Krajden M, van Niekerk DJ, Coldman AJ.

Int J Cancer. 2015 Oct 15;137(8):1931-7. doi: 10.1002/ijc.29508. Epub 2015 Jun 3.

26.

HAART slows progression to anal cancer in HIV-infected MSM.

Duncan KC, Chan KJ, Chiu CG, Montaner JS, Coldman AJ, Cescon A, Au-Yeung CG, Wiseman SM, Hogg RS, Press NM.

AIDS. 2015 Jan 28;29(3):305-11. doi: 10.1097/QAD.0000000000000537.

PMID:
25686679
27.

Public engagement in priority-setting: results from a pan-Canadian survey of decision-makers in cancer control.

Regier DA, Bentley C, Mitton C, Bryan S, Burgess MM, Chesney E, Coldman A, Gibson J, Hoch J, Rahman S, Sabharwal M, Sawka C, Schuckel V, Peacock SJ.

Soc Sci Med. 2014 Dec;122:130-9. doi: 10.1016/j.socscimed.2014.10.038. Epub 2014 Oct 18.

PMID:
25441325
28.

Women's intentions to self-collect samples for human papillomavirus testing in an organized cervical cancer screening program.

Smith LW, Khurshed F, van Niekerk DJ, Krajden M, Greene SB, Hobbs S, Coldman AJ, Franco EL, Ogilvie GS.

BMC Public Health. 2014 Oct 10;14:1060. doi: 10.1186/1471-2458-14-1060.

29.

Pan-Canadian study of mammography screening and mortality from breast cancer.

Coldman A, Phillips N, Wilson C, Decker K, Chiarelli AM, Brisson J, Zhang B, Payne J, Doyle G, Ahmad R.

J Natl Cancer Inst. 2014 Oct 1;106(11). pii: dju261. doi: 10.1093/jnci/dju261. Print 2014 Nov. Erratum in: J Natl Cancer Inst. 2015 Jan;107(1):dju404 doi:10.1093/jnci/dju404.

PMID:
25274578
30.

Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.

Pataky R, Ismail Z, Coldman AJ, Elwood M, Gelmon K, Hedden L, Hislop G, Kan L, McCoy B, Olivotto IA, Peacock S.

J Med Screen. 2014 Dec;21(4):180-8. doi: 10.1177/0969141314549758. Epub 2014 Sep 3.

PMID:
25186116
31.

Stage, treatment and outcomes for patients with breast cancer in British Columbia in 2002: a population-based cohort study.

Davidson A, Chia S, Olson R, Nichol A, Speers C, Coldman AJ, Bajdik C, Woods R, Tyldesley S.

CMAJ Open. 2013 Nov 7;1(4):E134-41. doi: 10.9778/cmajo.20130017. eCollection 2013 Oct.

32.

Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.

Pataky R, Gulati R, Etzioni R, Black P, Chi KN, Coldman AJ, Pickles T, Tyldesley S, Peacock S.

Int J Cancer. 2014 Aug 15;135(4):939-47. doi: 10.1002/ijc.28732. Epub 2014 Feb 4.

33.

Breast cancer survival and prognosis by screening history.

Coldman AJ, Phillips N.

Br J Cancer. 2014 Feb 4;110(3):556-9. doi: 10.1038/bjc.2013.732. Epub 2013 Dec 3.

34.

Assessing the breast cancer risk distribution for women undergoing screening in British Columbia.

Weisstock CR, Rajapakshe R, Bitgood C, McAvoy S, Gordon PB, Coldman AJ, Parker BA, Wilson C.

Cancer Prev Res (Phila). 2013 Oct;6(10):1084-92. doi: 10.1158/1940-6207.CAPR-13-0027. Epub 2013 Aug 20.

35.

Cost-effectiveness of MRI for breast cancer screening in BRCA1/2 mutation carriers.

Pataky R, Armstrong L, Chia S, Coldman AJ, Kim-Sing C, McGillivray B, Scott J, Wilson CM, Peacock S.

BMC Cancer. 2013 Jul 10;13:339. doi: 10.1186/1471-2407-13-339.

36.

Women's intentions to receive cervical cancer screening with primary human papillomavirus testing.

Ogilvie GS, Smith LW, van Niekerk DJ, Khurshed F, Krajden M, Saraiya M, Goel V, Rimer BK, Greene SB, Hobbs S, Coldman AJ, Franco EL.

Int J Cancer. 2013 Dec 15;133(12):2934-43. doi: 10.1002/ijc.28324. Epub 2013 Jul 16.

37.

Incidence of breast cancer and estimates of overdiagnosis after the initiation of a population-based mammography screening program.

Coldman A, Phillips N.

CMAJ. 2013 Jul 9;185(10):E492-8. doi: 10.1503/cmaj.121791. Epub 2013 Jun 10.

38.
39.

Population-based evaluation of type-specific HPV prevalence among women in British Columbia, Canada.

Ogilvie GS, Cook DA, Taylor DL, Rank C, Kan L, Yu A, Mei W, van Niekerk DJ, Coldman AJ, Krajden M.

Vaccine. 2013 Feb 4;31(7):1129-33. doi: 10.1016/j.vaccine.2012.09.085. Epub 2012 Dec 25.

PMID:
23273510
40.

Primary cervical cancer screening with HPV testing compared with liquid-based cytology: results of round 1 of a randomised controlled trial -- the HPV FOCAL Study.

Ogilvie GS, Krajden M, van Niekerk DJ, Martin RE, Ehlen TG, Ceballos K, Smith LW, Kan L, Cook DA, Peacock S, Stuart GC, Franco EL, Coldman AJ.

Br J Cancer. 2012 Dec 4;107(12):1917-24. doi: 10.1038/bjc.2012.489. Epub 2012 Nov 20.

41.

Effect of community population size on breast cancer screening, stage distribution, treatment use and outcomes.

Olson RA, Nichol A, Caron NR, Olivotto IA, Speers C, Chia S, Davidson A, Coldman A, Bajdik C, Tyldesley S.

Can J Public Health. 2012 Jan-Feb;103(1):46-52.

PMID:
22338328
42.

Population studies of the effectiveness of mammographic screening.

Coldman A, Phillips N.

Prev Med. 2011 Sep;53(3):115-7. doi: 10.1016/j.ypmed.2011.07.005. Epub 2011 Jul 21.

PMID:
21798279
43.

Surveillance after treatment for cervical intraepithelial neoplasia: outcomes, costs, and cost-effectiveness.

Melnikow J, Kulasingam S, Slee C, Helms LJ, Kuppermann M, Birch S, McGahan CE, Coldman A, Chan BK, Sawaya GF.

Obstet Gynecol. 2010 Nov;116(5):1158-70. doi: 10.1097/AOG.0b013e3181f88e72.

PMID:
20966702
44.

A randomized controlled trial of Human Papillomavirus (HPV) testing for cervical cancer screening: trial design and preliminary results (HPV FOCAL Trial).

Ogilvie GS, van Niekerk DJ, Krajden M, Martin RE, Ehlen TG, Ceballos K, Peacock SJ, Smith LW, Kan L, Cook DA, Mei W, Stuart GC, Franco EL, Coldman AJ.

BMC Cancer. 2010 Mar 24;10:111. doi: 10.1186/1471-2407-10-111.

45.

Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study.

Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A.

J Natl Cancer Inst. 2009 May 20;101(10):721-8. doi: 10.1093/jnci/djp089. Epub 2009 May 12.

46.

Impact of changing from annual to biennial mammographic screening on breast cancer outcomes in women aged 50-79 in British Columbia.

Coldman AJ, Phillips N, Olivotto IA, Gordon P, Warren L, Kan L.

J Med Screen. 2008;15(4):182-7. doi: 10.1258/jms.2008.008064.

PMID:
19106258
47.

Loss of desmoglein 1 expression associated with worse prognosis in head and neck squamous cell carcinoma patients.

Wong MP, Cheang M, Yorida E, Coldman A, Gilks CB, Huntsman D, Berean K.

Pathology. 2008 Oct;40(6):611-6. doi: 10.1080/00313020802320614.

PMID:
18752129
49.

Identification of prognostically relevant and reproducible subsets of endometrial adenocarcinoma based on clustering analysis of immunostaining data.

Alkushi A, Clarke BA, Akbari M, Makretsov N, Lim P, Miller D, Magliocco A, Coldman A, van de Rijn M, Huntsman D, Parker R, Gilks CB.

Mod Pathol. 2007 Nov;20(11):1156-65. Epub 2007 Aug 24.

50.

The impact of new chemotherapeutic and hormone agents on survival in a population-based cohort of women with metastatic breast cancer.

Chia SK, Speers CH, D'yachkova Y, Kang A, Malfair-Taylor S, Barnett J, Coldman A, Gelmon KA, O'reilly SE, Olivotto IA.

Cancer. 2007 Sep 1;110(5):973-9.

Supplemental Content

Loading ...
Support Center